{"id":743796,"date":"2013-04-24T06:30:00","date_gmt":"2013-04-24T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/"},"modified":"2023-03-22T00:04:39","modified_gmt":"2023-03-22T04:04:39","slug":"merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/","title":{"rendered":"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the U.S. Food and Drug Administration (FDA) has<br \/>\n      designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the<br \/>\n      treatment of patients with advanced melanoma. Lambrolizumab is Merck\u2019s<br \/>\n      investigational antibody therapy targeting Programmed Death receptor<br \/>\n      (PD-1) that is currently being evaluated for the treatment of patients<br \/>\n      with advanced melanoma, and other tumor types.\n    <\/p>\n<p>\n      \u201cWe are pleased that the FDA has designated lambrolizumab a Breakthrough<br \/>\n      Therapy for patients with advanced melanoma,\u201d said Gary Gilliland M.D.,<br \/>\n      Ph.D., senior vice president and oncology franchise head, Merck Research<br \/>\n      Laboratories. \u201cThe FDA\u2019s decision to place lambrolizumab in a category<br \/>\n      that may enable expedited development and review is an important<br \/>\n      milestone for Merck as we advance ongoing programs in multiple cancer<br \/>\n      indications.\u201d\n    <\/p>\n<p>\n      The designation of an investigational drug as a Breakthrough Therapy is<br \/>\n      intended to expedite the development and review of a candidate that is<br \/>\n      planned for use, alone or in combination, to treat a serious or<br \/>\n      life-threatening disease or condition when preliminary clinical evidence<br \/>\n      indicates that the drug may demonstrate substantial improvement over<br \/>\n      existing therapies on one or more clinically significant endpoints. The<br \/>\n      Food and Drug Administration Safety and Innovation Act (FDASIA) includes<br \/>\n      a provision that allows sponsors to request that an investigational drug<br \/>\n      be designated as a Breakthrough Therapy. The implications of<br \/>\n      Breakthrough Therapy Designation cannot be determined at this time.\n    <\/p>\n<p>\n      In November 2012, early interim results from a single-arm, open-label<br \/>\n      Phase Ib study of lambrolizumab (MK-3475) administered to 85 patients<br \/>\n      with advanced (inoperable and metastatic) melanoma were presented at the<br \/>\n      Society for Melanoma Research of the 9th International Congress of the<br \/>\n      Society for Melanoma Research (SMR) in Hollywood, Calif. (see <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Fresearch-and-development-news%2Fmerck-presents-early-stage-interim-data-mk-3475-investig&#038;esheet=50616739&#038;lan=en-US&#038;anchor=news+release&#038;index=1&#038;md5=c50f619fc8a3fe09afe6cdc5a7a6fca0\">news<br \/>\n      release<\/a>).\n    <\/p>\n<p>\n      <b>Advanced melanoma<\/b>\n    <\/p>\n<p>\n      Advanced melanoma accounts for more than 80 percent of skin<br \/>\n      cancer-related deaths and one to two percent of all cancer deaths in the<br \/>\n      United States<sup>1<\/sup>. According to the <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.cancer.org%2Fresearch%2Fcancerfactsfigures%2Fcancerfactsfigures%2Fcancer-facts-figures-2012&#038;esheet=50616739&#038;lan=en-US&#038;anchor=American+Cancer+Society&#038;index=2&#038;md5=7db0c62ee2f4b0ce7debf2b2fd054d86\">American<br \/>\n      Cancer Society<\/a>, in 2012 in the U.S. an estimated 9,180 people died<br \/>\n      from advanced melanoma.\n    <\/p>\n<p>\n      <b>About PD-1<\/b>\n    <\/p>\n<p>\n      Researchers have shown that several tumor types are able to hide in<br \/>\n      plain sight by establishing a \u201cmolecular camouflage\u201d that deceives the<br \/>\n      body\u2019s immune system into thinking they are normal and therefore allow<br \/>\n      them to grow unchecked. The interaction between the immune checkpoint<br \/>\n      receptor PD-1 (programmed death) and its ligands represents a<br \/>\n      potentially important tumor-specific immunomodulatory mechanism. By<br \/>\n      utilizing the PD-1 pathway, a tumor cell can prevent the activation of<br \/>\n      T-cells and therefore may block a key step that triggers the immune<br \/>\n      system.\n    <\/p>\n<p>\n      <b>About lambrolizumab<\/b>\n    <\/p>\n<p>\n      Lambrolizumab is an investigational antibody therapy designed to disrupt<br \/>\n      the action of the immune checkpoint protein PD-1 and therefore inhibit<br \/>\n      the ability of some cancers to evade the body\u2019s immune system.<br \/>\n      Lambrolizumab is being studied in multiple cancer types including<br \/>\n      melanoma and non-small cell lung cancer. For further details, please<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DMK-3475%26Search%3DSearch&#038;esheet=50616739&#038;lan=en-US&#038;anchor=http%3A%2F%2Fclinicaltrials.gov&#038;index=3&#038;md5=4f92322aee62673b21f0d2ff589f0e18\">http:\/\/clinicaltrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50616739&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=4&#038;md5=d719e04729e03173f62e07b91d6a2f43\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.twitter%2FMerck&#038;esheet=50616739&#038;lan=en-US&#038;anchor=Twitter&#038;index=5&#038;md5=ef0435ea7cf70ad0ddb65b4482e6f328\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50616739&#038;lan=en-US&#038;anchor=Facebook&#038;index=6&#038;md5=619b415b87368c419d47bfe0c50346a5\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50616739&#038;lan=en-US&#038;anchor=YouTube&#038;index=7&#038;md5=cd797922af76cc0bd290e21bdc3f8482\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50616739&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=8&#038;md5=a3231216b49a5b6b10a84517ed003e18\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fmy.clevelandclinic.org%2Fdisorders%2Fskin_cancer%2Fhic_the_facts_about_melanoma.aspx&#038;esheet=50616739&#038;lan=en-US&#038;anchor=http%3A%2F%2Fmy.clevelandclinic.org%2Fdisorders%2Fskin_cancer%2Fhic_the_facts_about_melanoma.aspx&#038;index=9&#038;md5=87ed5cce90e904431bf31785cfe49b63\">http:\/\/my.clevelandclinic.org\/disorders\/skin_cancer\/hic_the_facts_about_melanoma.aspx<\/a><br \/>\n      Accessed on April 17, 2013\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130424005254r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Caroline Lapppetito, 267-305-7639<br \/>or<br \/>Investors:<br \/>Carol        Ferguson, 908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Merck\u2019s investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. \u201cWe are pleased that the FDA has designated lambrolizumab a Breakthrough Therapy for patients with advanced melanoma,\u201d said Gary Gilliland M.D., Ph.D., senior vice president and oncology franchise head, Merck Research Laboratories. \u201cThe FDA\u2019s decision to place lambrolizumab in a category that may enable expedited development and review is an important milestone for Merck as we advance ongoing programs in multiple cancer indications.\u201d The designation of an investigational drug as a Breakthrough Therapy is intended to expedite<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,56],"class_list":["post-743796","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Merck\u2019s investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. \u201cWe are pleased that the FDA has designated lambrolizumab a Breakthrough Therapy for patients with advanced melanoma,\u201d said Gary Gilliland M.D., Ph.D., senior vice president and oncology franchise head, Merck Research Laboratories. \u201cThe FDA\u2019s decision to place lambrolizumab in a category that may enable expedited development and review is an important milestone for Merck as we advance ongoing programs in multiple cancer indications.\u201d The designation of an investigational drug as a Breakthrough Therapy is intended to expedite\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:39+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/\",\"name\":\"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-04-24T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma. Lambrolizumab is Merck\u2019s investigational antibody therapy targeting Programmed Death receptor (PD-1) that is currently being evaluated for the treatment of patients with advanced melanoma, and other tumor types. \u201cWe are pleased that the FDA has designated lambrolizumab a Breakthrough Therapy for patients with advanced melanoma,\u201d said Gary Gilliland M.D., Ph.D., senior vice president and oncology franchise head, Merck Research Laboratories. \u201cThe FDA\u2019s decision to place lambrolizumab in a category that may enable expedited development and review is an important milestone for Merck as we advance ongoing programs in multiple cancer indications.\u201d The designation of an investigational drug as a Breakthrough Therapy is intended to expedite","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:39+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/","name":"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx","datePublished":"2013-04-24T06:30:00+00:00","dateModified":"2023-03-22T04:04:39+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130424005254r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-breakthrough-therapy-designation-for-lambrolizumab-an-investigational-antibody-therapy-for-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f5cde897-2864-4a51-a2b1-6e732a73d37a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743796\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743796"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}